SCHEMBL13009753

SCHEMBL13009753

COC(=O)CC1(C)CCN(c2ccc([N+](=O)[O-])cn2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.55
ALDH1A1 P00352 4/20 0.54
LMNA P02545 2/20 0.54
ALOX12 P18054 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
CYP1A2 P05177 1/20 0.52
CYP2C9 P11712 1/20 0.52
HPGD P15428 1/20 0.52
CRBN Q96SW2 3/20 0.52
MEN1 O00255 5/20 0.50
KMT2A Q03164 5/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
ATM Q13315 1/20 0.50
POLB P06746 1/20 0.50
MAPK1 P28482 2/20 0.48
KDM4E B2RXH2 1/20 0.48
PANK3 Q9H999 1/20 0.48
NPBWR1 P48145 1/20 0.47
MCHR1 Q99705 1/20 0.47
PKM P14618 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25169802 0.90 MAPT (0.54) MAPTALDH1A1LMNAALOX12NPSR1
SCHEMBL3546927 0.87 MAPT (0.59) MAPTALDH1A1LMNAALOX12NPSR1
SCHEMBL3546922 0.87 MAPT (0.59) MAPTALDH1A1LMNAALOX12NPSR1
SCHEMBL13009756 0.82 CRBN (0.42) ALDH1A1HPGDCRBNKMT2A
SCHEMBL3537802 0.82 MAPT (0.59) MAPTALDH1A1LMNAALOX12NPSR1
SCHEMBL25447008 0.81 MAPT (0.58) MAPTALDH1A1LMNAALOX12NPSR1
SCHEMBL16969449 0.81 MAPT (0.53) MAPTALDH1A1LMNAALOX12NPSR1
SCHEMBL596528 0.80 MAPT (0.62) MAPTALDH1A1LMNAALOX12NPSR1
SCHEMBL13009759 0.79 TRPV1 (0.44) MAPTALDH1A1LMNACYP1A2CRBN
SCHEMBL3536979 0.78 TRPV1 (0.44) MAPTALDH1A1LMNACYP1A2CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2010-12-16 US disclosed
US-7795283-B2 Oxadiazole derivative as DGAT inhibitors ASTRAZENECA AB (SE) 2010-09-14 US disclosed
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors ASTRAZENECA AB (SE) 2008-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS DGAT1, DGAT2, GPR119 MAPT 2115/4885ALDH1A1 314/4885LMNA 3296/4885
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors DGAT1, DGAT2, GPR119 MAPT 1986/4885ALDH1A1 303/4885LMNA 3477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.